Hypertension and urologic chronic pelvic pain syndrome: An analysis of MAPP-I data.

Rosalynn R Z Conic, Terrie Vasilopoulos, Karthik Devulapally, Rene Przkora, Andrew Dubin, Kimberly T Sibille, Aaron D Mickle
Author Information
  1. Rosalynn R Z Conic: Department of Physical Medicine and Rehabilitation, College of Medicine, University of Florida, Gainesville, FL, USA.
  2. Terrie Vasilopoulos: Department of Orthopaedic Surgery and Sports Medicine, University of Florida, Gainesville, FL, USA.
  3. Karthik Devulapally: Department of Physiological Sciences, College of Veterinary Medicine, University of Florida, PO Box 100144, Gainesville, FL, 32610, USA.
  4. Rene Przkora: Department of Anesthesiology, Division of Pain Medicine, University of Florida, Gainesville, FL, USA.
  5. Andrew Dubin: Department of Physical Medicine and Rehabilitation, College of Medicine, University of Florida, Gainesville, FL, USA.
  6. Kimberly T Sibille: Department of Physical Medicine and Rehabilitation, College of Medicine, University of Florida, Gainesville, FL, USA.
  7. Aaron D Mickle: Department of Physiological Sciences, College of Veterinary Medicine, University of Florida, PO Box 100144, Gainesville, FL, 32610, USA. amickle@ufl.edu.

Abstract

BACKGROUND: Urologic chronic pelvic pain syndrome (UCPPS), which includes interstitial cystitis/bladder pain syndrome (IC/BPS) and chronic prostatitis (CP/CPPS), is associated with increased voiding frequency, nocturia, and chronic pelvic pain. The cause of these diseases is unknown and likely involves many different mechanisms. Dysregulated renin-angiotensin-aldosterone-system (RAAS) signaling is a potential pathologic mechanism for IC/BPS and CP/CPPS. Many angiotensin receptor downstream signaling factors, including oxidative stress, fibrosis, mast cell recruitment, and increased inflammatory mediators, are present in the bladders of IC/BPS patients and prostates of CP/CPPS patients. Therefore, we aimed to test the hypothesis that UCPPS patients have dysregulated angiotensin signaling, resulting in increased hypertension compared to controls. Secondly, we evaluated symptom severity in patients with and without hypertension and antihypertensive medication use.
METHODS: Data from UCPPS patients (n���=���424), fibromyalgia or irritable bowel syndrome (positive controls, n���=���200), and healthy controls (n���=���415) were obtained from the NIDDK Multidisciplinary Approach to the Study of Chronic Pelvic Pain I (MAPP-I). Diagnosis of hypertension, current antihypertensive medications, pain severity, and urinary symptom severity were analyzed using chi-square test and t-test.
RESULTS: The combination of diagnosis and antihypertensive medications use was highest in the UCPPS group (n���=���74, 18%), followed by positive (n���=���34, 17%) and healthy controls (n���=���48, 12%, p���=���0.04). There were no differences in symptom severity based on hypertension in UCPPS and CP/CPPS; however, IC/BPS had worse ICSI (p���=���0.031), AUA-SI (p���=���0.04), and BPI pain severity (0.02). Patients (n���=���7) with a hypertension diagnosis not on antihypertensive medications reported the greatest severity of pain and urinary symptoms.
CONCLUSION: This pattern of findings suggests that there may be a relationship between hypertension and UCPPS. Treating hypertension among these patients may result in reduced pain and symptom severity. Further investigation on the relationship between hypertension, antihypertensive medication use, and UCPPS and the role of angiotensin signaling in UCPPS conditions is needed.

Keywords

References

  1. Sci Rep. 2017 Aug 21;7(1):8872 [PMID: 28827631]
  2. J Renin Angiotensin Aldosterone Syst. 2014 Dec;15(4):329-40 [PMID: 25503939]
  3. Urol Clin North Am. 1995 May;22(2):291-8 [PMID: 7539175]
  4. Histopathology. 2010 Sep;57(3):371-83 [PMID: 20840668]
  5. Am J Kidney Dis. 1996 Oct;28(4):603-9 [PMID: 8840953]
  6. J Urol. 2005 Feb;173(2):625-9 [PMID: 15643277]
  7. J Urol. 1992 Dec;148(6):1951-6 [PMID: 1433651]
  8. Urology. 2013 Nov;82(5):1103-7 [PMID: 23953604]
  9. Neurourol Urodyn. 2013 Mar;32(3):287-92 [PMID: 22847258]
  10. Kidney Int Suppl (2011). 2014 Nov;4(1):58-64 [PMID: 26312151]
  11. Inflammation. 2013 Jun;36(3):651-7 [PMID: 23250825]
  12. Int Urol Nephrol. 2015 Aug;47(8):1297-302 [PMID: 26049975]
  13. Int Urogynecol J. 2021 May;32(5):1299-1306 [PMID: 33215272]
  14. PLoS One. 2016 Sep 29;11(9):e0163829 [PMID: 27684718]
  15. Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13607-12 [PMID: 15342908]
  16. PLoS One. 2013 May 15;8(5):e64630 [PMID: 23691256]
  17. J Pain Res. 2018 Jul 25;11:1367-1374 [PMID: 30100751]
  18. Circulation. 2012 Oct 23;126(17):2105-14 [PMID: 23091084]
  19. Am J Respir Crit Care Med. 2000 Jun;161(6):1999-2004 [PMID: 10852780]
  20. J Urol. 2011 Aug;186(2):540-4 [PMID: 21683389]
  21. J Urol. 2010 Mar;183(3):1206-12 [PMID: 20096889]
  22. Neurourol Urodyn. 2014 Jun;33(5):511-5 [PMID: 23813657]
  23. Urology. 1997 May;49(5A Suppl):58-63 [PMID: 9146003]
  24. Acta Histochem. 2007;109(3):208-14 [PMID: 17287017]
  25. Int J Urol. 2012 May;19(5):457-64 [PMID: 22320898]
  26. Neurourol Urodyn. 2021 Jan;40(1):102-111 [PMID: 33074588]
  27. Neurourol Urodyn. 2015 Jan;34(1):86-91 [PMID: 24151066]
  28. Pharmacol Ther. 2006 Dec;112(3):668-76 [PMID: 16837049]
  29. EMBO Mol Med. 2010 Jul;2(7):247-57 [PMID: 20597104]
  30. J Hum Hypertens. 2007 Jan;21(1):20-7 [PMID: 17096009]
  31. Int J Environ Res Public Health. 2022 May 26;19(11): [PMID: 35682067]
  32. Am J Physiol Renal Physiol. 2016 Jul 1;311(1):F85-93 [PMID: 27122537]
  33. Int J Impot Res. 1997 Sep;9(3):135-40 [PMID: 9315490]
  34. Adv Exp Med Biol. 1999;462:183-91 [PMID: 10599423]
  35. Ann Acad Med Singap. 1994 Mar;23(2):129-38 [PMID: 8080219]
  36. Indian J Urol. 2016 Jan-Mar;32(1):34-9 [PMID: 26941492]
  37. Histopathology. 2017 Sep;71(3):415-424 [PMID: 28394416]
  38. NCHS Data Brief. 2020 Apr;(364):1-8 [PMID: 32487290]
  39. Urology. 2008 Feb;71(2):261-6 [PMID: 18308097]
  40. Hepatology. 2001 Oct;34(4 Pt 1):745-50 [PMID: 11584371]
  41. BJU Int. 2017 Jul;120(1):130-142 [PMID: 28263447]
  42. J Urol. 1999 Aug;162(2):327-9 [PMID: 10411031]
  43. Front Pain Res (Lausanne). 2022 Aug 24;3:925834 [PMID: 36093391]
  44. Int J Cardiol Hypertens. 2020 Jul 31;6:100044 [PMID: 33447770]
  45. BMC Urol. 2020 Oct 7;20(1):154 [PMID: 33028277]
  46. Am J Physiol. 1994 Jun;266(6 Pt 2):R1861-7 [PMID: 8024040]
  47. Sci Rep. 2019 May 31;9(1):8134 [PMID: 31148586]
  48. J Urol. 2015 Nov;194(5):1295-300 [PMID: 26070893]
  49. J Neuroinflammation. 2020 Jun 12;17(1):183 [PMID: 32532285]
  50. Urol Int. 2015;95(2):227-32 [PMID: 26184102]
  51. Arch Physiol Biochem. 2021 Feb;127(1):1-5 [PMID: 30739509]
  52. Urology. 2014 Aug;84(2):321-6 [PMID: 24958479]
  53. Urology. 2001 Jun;57(6 Suppl 1):47-55 [PMID: 11378050]
  54. Urology. 2009 Nov;74(5):983-7, quiz 987.e1-3 [PMID: 19800663]
  55. Am J Hypertens. 2013 Oct;26(10):1224-33 [PMID: 23761490]
  56. J Urol. 2007 Dec;178(6):2411-5; discussion 2415 [PMID: 17937946]
  57. J Endocrinol Invest. 2017 Nov;40(11):1209-1218 [PMID: 28488229]
  58. BJU Int. 2005 Sep;96(4):559-65 [PMID: 16104910]
  59. Nat Rev Endocrinol. 2009 Jul;5(7):374-81 [PMID: 19488073]
  60. Stem Cells Dev. 2015 Jul 15;24(14):1648-57 [PMID: 25745847]
  61. Sci Rep. 2018 Jun 28;8(1):9782 [PMID: 29955137]
  62. Nat Rev Urol. 2019 Mar;16(3):187-200 [PMID: 30560936]
  63. World J Urol. 2003 Jun;21(2):70-4 [PMID: 12712363]
  64. Transl Androl Urol. 2020 Apr;9(2):485-493 [PMID: 32420154]

Grants

  1. R01 DK132003/NIDDK NIH HHS
  2. DK132003/NIH HHS

MeSH Term

Male
Humans
Antihypertensive Agents
Chronic Pain
Cystitis, Interstitial
Pelvic Pain
Hypertension
Angiotensins

Chemicals

Antihypertensive Agents
Angiotensins

Word Cloud

Created with Highcharts 10.0.0painUCPPShypertensionseveritypatientschronicsyndromeantihypertensivepelvicIC/BPSCP/CPPSsignalingcontrolssymptomincreasedangiotensinusemedicationsp���=���0Urologiccystitis/bladderprostatitistestmedicationpositivehealthyChronicMAPP-Iurinarydiagnosis04mayrelationshipHypertensionBACKGROUND:includesinterstitialassociatedvoidingfrequencynocturiacausediseasesunknownlikelyinvolvesmanydifferentmechanismsDysregulatedrenin-angiotensin-aldosterone-systemRAASpotentialpathologicmechanismManyreceptordownstreamfactorsincludingoxidativestressfibrosismastcellrecruitmentinflammatorymediatorspresentbladdersprostatesThereforeaimedhypothesisdysregulatedresultingcomparedSecondlyevaluatedwithoutMETHODS:Datan���=���424fibromyalgiairritableboweln���=���200n���=���415obtainedNIDDKMultidisciplinaryApproachStudyPelvicPainDiagnosiscurrentanalyzedusingchi-squaret-testRESULTS:combinationhighestgroupn���=���7418%followedn���=���3417%n���=���4812%differencesbasedhoweverworseICSI031AUA-SIBPI002Patientsn���=���7reportedgreatestsymptomsCONCLUSION:patternfindingssuggestsTreatingamongresultreducedinvestigationroleconditionsneededurologicsyndrome:analysisdataAngiotensinInterstitialMAPP

Similar Articles

Cited By (1)